Efficacy of CDK 4/6 Inhibitors and Radiotherapy in Breast Cancer Patients with Brain Metastases

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy are the standard of care for HR-positive/HER2-negative advanced breast cancer patients. However, their role in the treatment of brain metastases is currently unclear. We retrospectively evaluate the results of patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Kubeczko, Marcin, Jarząb, Michał, Krzywon, Aleksandra, Gräupner, Donata, Polakiewicz-Gilowska, Anna, Gabryś, Dorota
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10004463/
https://www.ncbi.nlm.nih.gov/pubmed/36902831
http://dx.doi.org/10.3390/jcm12052044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10004463/
https://www.ncbi.nlm.nih.gov/pubmed/36902831
http://dx.doi.org/10.3390/jcm12052044

Ejemplares similares